Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …

Purpose: Multiple myeloma remains an incurable malignancy of plasma cells despite
considerable advances in treatment. The purpose of the study was to develop novel …

Immune checkpoint blockade antibodies and immunomodulatory drugs can unleash anti-
tumor T cell immunity and mediate durable cancer regressions. However, only a fraction of …

The therapy of relapsed chronic lymphocytic leukemia (CLL) has changed dramatically in
the past year with the regulatory approval of idelalisib and ibrutinib, with other therapeutic …

PD-1 blockade enhances the function of antitumor T cells and antibody-dependent, cell-
mediated cytotoxicity (ADCC) of NK cells. In a single-center, open-label, phase 2 trial, we …

Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits
immunomodulatory properties including the activation of T and NK cells. The use of …

Purpose Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic
lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response …

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in
disease progression and drug resistance in B cell malignancies, by supporting tumor growth …

The best initial therapy for elderly patients with chronic lymphocytic leukemia (CLL) has not
yet been defined. We investigated the activity of lenalidomide as initial therapy for elderly …